OPTI — OptiBiotix Health Share Price
Last trade - 00:00- £16.16m
- £15.27m
- £0.46m
- 51
- 50
- 40
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.78 | ||
| Price to Tang. Book | 2.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 23.45 | ||
| EV to EBITDA | 1.31 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 121.35% | ||
| Return on Equity | -85.62% | ||
| Operating Margin | 1656.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.51 | 0.74 | 1.52 | 2.21 | 0.46 | n/a | n/a | 19.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +102.32 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.
Directors
- Richard Davidson NEC
- Stephen O'hara CEO
- Sofia Kolyda EDR
- Taru Jainas OTH
- Mikkel Hvid-Hansen DRC (53)
- Christopher Brinsmead NED (62)
- Michael Christie NID (64)
- Stephen Hammond NID (59)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- July 19th, 2006
- Public Since
- September 9th, 2011
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 97,943,161
- Address
- Innovation Centre, HESLINGTON, Y010 5DG
- Web
- http://www.optibiotix.com
- Phone
- +44 2079338780
- Auditors
- Jeffreys Henry LLP
Latest News for OPTI
Upcoming Events for OPTI
Full Year 2023 OptiBiotix Health PLC Earnings Release
OptiBiotix Health PLC Annual Shareholders Meeting
Half Year 2024 OptiBiotix Health PLC Earnings Release
Similar to OPTI
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 22:30 UTC, shares in OptiBiotix Health are trading at 16.50p. This share price information is delayed by 15 minutes.
Shares in OptiBiotix Health last closed at 16.50p and the price had moved by +120% over the past 365 days. In terms of relative price strength the OptiBiotix Health share price has outperformed the FTSE All Share Index by +106.6% over the past year.
The overall consensus recommendation for OptiBiotix Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
OptiBiotix Health does not currently pay a dividend.
OptiBiotix Health does not currently pay a dividend.
OptiBiotix Health does not currently pay a dividend.
To buy shares in OptiBiotix Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 16.50p, shares in OptiBiotix Health had a market capitalisation of £16.16m.
Here are the trading details for OptiBiotix Health:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OPTI
Based on an overall assessment of its quality, value and momentum OptiBiotix Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OptiBiotix Health. Over the past six months, its share price has underperformed the FTSE All Share Index by -39.34%.
As of the last closing price of 16.50p, shares in OptiBiotix Health were trading -31.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The OptiBiotix Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 16.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
OptiBiotix Health's management team is headed by:
- Richard Davidson - NEC
- Stephen O'hara - CEO
- Sofia Kolyda - EDR
- Taru Jainas - OTH
- Mikkel Hvid-Hansen - DRC
- Christopher Brinsmead - NED
- Michael Christie - NID
- Stephen Hammond - NID